CF
ROIV icon

Cantor Fitzgerald’s Roivant Sciences ROIV Stock Holding History

Cantor Fitzgerald’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-350,001
Closed -$3.94M – 510
2025
Q2 		$3.94M Buy
+350,001
New +$3.79M 0.07% 70
2024
Q4 		– Sell
-195,000
Closed -$2.25M – 326
2024
Q3 		$2.25M Buy
+195,000
New +$2.22M 0.06% 47
2023
Q2 		– Sell
-1,091,602
Closed -$8.06M – 638
2023
Q1 		$8.06M Buy
+1,091,602
New +$8.99M 0.17% 186

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Cantor Fitzgerald's ROIV Position: Q3 2025 in Review

Cantor Fitzgerald sold out of Roivant Sciences (ROIV) in Q3 2025, closing a stake of 350,001 shares — an estimated $3.94M sold.

Cantor Fitzgerald first reported a position in ROIV in Q1 2023 and held it in 3 quarters. The position peaked at $8.06M in Q1 2023. 337 funds tracked by Wall St. Rank hold ROIV as of Q3 2025.

  • Cantor Fitzgerald reported no remaining Roivant Sciences position as of Q3 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 350,001 Roivant Sciences shares in Q3 2025, an estimated $3.94M.
  • Cantor Fitzgerald first reported a position in Roivant Sciences in Q1 2023 and held it in 3 quarters.
  • Cantor Fitzgerald's Roivant Sciences position peaked at $8.06M in Q1 2023.
  • 337 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2025.

Based on Cantor Fitzgerald's 13F filing for Q3 2025, filed 14 Nov 2025.